GeneDx Holdings
WGSNASDAQUSD
- Source valuation snapshot. Not a live recalculation.
- Latest filed annual earnings; price snapshot date unavailable. Not forward P/E.
- Diluted earnings per share from the latest filed annual.
- $54.83 Prior regular-session close from the quote source.
- $54.73–$59.72 Regular-session low and high so far today.
- 1.1M Regular-session shares traded · Nov 11, 4:00 PM ET.
- Jan 11 projected Projected for 2027-01-11 from the company’s own results filings (SEC 8-K Item 2.02). The company has not confirmed the date.
- $32.21–$170.87 52-week trading low and high returned by the quote source.
Understand the Business
Why the Stock Moved
Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.
The core investment thesis
Own WGS if exome/genome testing becomes a routinely reimbursed first-line diagnostic tool and the company keeps converting that volume into higher lab utilization, gross margin, and cash generation.
WGS price history
Loading recent earnings…
Investment thesis
What must happen next
Clinician adoption and payer acceptance of broad genetic testing continue to expand GeneDx’s addressable diagnostic volume rather than reverting to narrower, cheaper tests.StrengtheningMateriality: High
GAAP annual revenue increased from $202.6 million in FY2023 to $305.5 million in FY2024 and $427.5 million in FY2025. If this holds, GeneDx can keep growing from clinical demand; if it breaks, revenue growth becomes vulnerable to test-volume and reimbursement pressure.
Watch: Major payers tighten medical-necessity criteria for exome/genome sequencing or push patients back toward narrower panels.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual revenue increased from $202.6 million in FY2023 to $305.5 million in FY2024 and $427.5 million in FY2025.
Open source ↗GeneDx’s lab scale, test mix, and interpretation workflow keep improving unit economics so incremental testing produces high gross profit rather than commodity lab margins.StrengtheningMateriality: High
GAAP annual gross profit improved from negative $26.8 million in FY2022 to $90.0 million in FY2023, $194.4 million in FY2024, and $298.2 million in FY2025. This is the difference between attractive genomic diagnostics scale and low-return volume growth.
Watch: Payers reduce reimbursement for exome/genome tests faster than GeneDx can lower sequencing and interpretation costs.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual gross profit improved from negative $26.8 million in FY2022 to $90.0 million in FY2023, $194.4 million in FY2024.
Open source ↗The post-Sema4 operating model remains focused enough that growth flows through fixed lab, technology, and corporate infrastructure instead of being consumed by sales, R&D, and overhead expansion.StrengtheningMateriality: Medium
GAAP annual operating loss narrowed from $667.7 million in FY2022 to $180.6 million in FY2023, $23.2 million in FY2024, and $13.1 million in FY2025. Operating leverage would let shareholders benefit from scale; loss of discipline would make GeneDx a permanently expensive growth lab.
Watch: Management restarts broad platform or non-core data initiatives that raise fixed costs before clear reimbursement demand exists.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual operating loss narrowed from $667.7 million in FY2022 to $180.6 million in FY2023, $23.2 million in FY2024, and.
Open source ↗GeneDx’s reimbursement and billing processes are maturing enough that accounting revenue converts into cash rather than being trapped in denials, appeals, and receivables.StrengtheningMateriality: Medium
GAAP annual operating cash flow improved from negative $180.1 million in FY2023 to negative $28.5 million in FY2024 and positive $33.3 million in FY2025. Positive cash conversion lowers financing risk and makes the growth self-funding; poor collections would undermine even strong reported revenue.
Watch: Commercial payers or government programs increase claim denials, audits, or recoupments for broad genetic testing.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual operating cash flow improved from negative $180.1 million in FY2023 to negative $28.5 million in FY2024 and positive.
Open source ↗The balance sheet gives GeneDx enough room to fund commercialization and lab capacity without relying on punitive financing, provided cash generation does not reverse.StrengtheningMateriality: Medium
Cash was $105.0 million at FY2025, up from $85.2 million at FY2024. If the runway holds, per-share value can accrue to current holders; if it fails, dilution or debt could absorb much of the operating upside.
Watch: A reimbursement shock or competitive price cut returns the company to sustained cash burn.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Cash was $105.0 million at FY2025, up from $85.2 million at FY2024.
Open source ↗
Full investment case & evidence
Loading the original research archive…
Original research
Clinician adoption and payer acceptance of broad genetic testing continue to expand GeneDx’s addressable diagnostic volume rather than reverting to narrower, cheaper tests. If this holds, GeneDx can keep growing from clinical demand; if it breaks, revenue growth becomes vulnerable to test-volume and reimbursement pressure.
GeneDx’s lab scale, test mix, and interpretation workflow keep improving unit economics so incremental testing produces high gross profit rather than commodity lab margins. This is the difference between attractive genomic diagnostics scale and low-return volume growth.
The post-Sema4 operating model remains focused enough that growth flows through fixed lab, technology, and corporate infrastructure instead of being consumed by sales, R&D, and overhead expansion. Operating leverage would let shareholders benefit from scale; loss of discipline would make GeneDx a permanently expensive growth lab.
GeneDx’s reimbursement and billing processes are maturing enough that accounting revenue converts into cash rather than being trapped in denials, appeals, and receivables. Positive cash conversion lowers financing risk and makes the growth self-funding; poor collections would undermine even strong reported revenue.
The balance sheet gives GeneDx enough room to fund commercialization and lab capacity without relying on punitive financing, provided cash generation does not reverse. If the runway holds, per-share value can accrue to current holders; if it fails, dilution or debt could absorb much of the operating upside.
All standing thesis claims
Original report summary
exome/genome testing becomes a routinely reimbursed first-line diagnostic tool and the company keeps converting that volume into higher lab utilization, gross margin, and cash generation.
Bull case and bear case
Bull case and bear case for GeneDx Holdings
Where the evidence on GeneDx Holdings stands: Strengthening on the latest evidence (Oct 19, 2026). Of its 5 thesis points, 5 strengthening.
Bull case: what the evidence supports
Clinician adoption and payer acceptance of broad genetic testing continue to expand GeneDx’s addressable diagnostic volume rather than reverting to narrower, cheaper tests.
GeneDx’s lab scale, test mix, and interpretation workflow keep improving unit economics so incremental testing produces high gross profit rather than commodity lab margins.
The post-Sema4 operating model remains focused enough that growth flows through fixed lab, technology, and corporate infrastructure instead of being consumed by sales, R&D, and overhead expansion.
GeneDx’s reimbursement and billing processes are maturing enough that accounting revenue converts into cash rather than being trapped in denials, appeals, and receivables.
The balance sheet gives GeneDx enough room to fund commercialization and lab capacity without relying on punitive financing, provided cash generation does not reverse.
Bear case: what would count against it
Major payers tighten medical-necessity criteria for exome/genome sequencing or push patients back toward narrower panels.
Payers reduce reimbursement for exome/genome tests faster than GeneDx can lower sequencing and interpretation costs.
Management restarts broad platform or non-core data initiatives that raise fixed costs before clear reimbursement demand exists.
Thesis-Break Engine
Thesis-break watch · GeneDx Holdings
No break has crossed GeneDx Holdings’s thesis. Its break conditions are checked against every new filing as it lands.
MARKET + FINANCIAL SNAPSHOT
The numbers behind the thesis
What Changed
- MixedReported results of operations (earnings release).
GeneDx Holdings filed an SEC 8-K on 2026-08-03: Reported results of operations (earnings release). It is a dated development that tests the current thesis.
- MixedDirector or principal officer change.
GeneDx Holdings filed an SEC 8-K on 2026-06-16: Director or principal officer change. It is a dated development that tests the current thesis.
- MixedReported results of operations (earnings release).
GeneDx Holdings filed an SEC 8-K on 2026-05-04: Reported results of operations (earnings release). It is a dated development that tests the current thesis.
Risks / falsifiers
What could break the thesis
- Major payers tighten medical-necessity criteria for exome/genome sequencing or push patients back toward narrower panels.
- Payers reduce reimbursement for exome/genome tests faster than GeneDx can lower sequencing and interpretation costs.
- Management restarts broad platform or non-core data initiatives that raise fixed costs before clear reimbursement demand exists.
- Commercial payers or government programs increase claim denials, audits, or recoupments for broad genetic testing.
- A reimbursement shock or competitive price cut returns the company to sustained cash burn.
WGS news
Loading headlines…
Financial statements
WGS income statement
Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.
WGS: quick answers
- When does GeneDx Holdings (WGS) report earnings next?
- GeneDx Holdings's next results are projected for January 11, 2027, from the dates of its own results filings with the SEC. The company has not confirmed the date. It last reported on November 9, 2026. Earnings calendar
- What is WGS's short interest?
- As of October 30, 2026, 6.6M WGS shares were sold short, 21.9% of its shares outstanding, up 8.8% from the count before. At the stock's average daily volume that is 7.3 days to cover. FINRA publishes the count twice a month. WGS short interest history
- Which well-known investors own WGS?
- 1 of the 37 well-known funds tracked here reported WGS shares in their latest 13F filing. By share of the fund's portfolio: ARK Investment Management (Cathie Wood), 0.7%. Fund portfolios
WGS in well-known investors’ portfolios
1 of 37 funds reported WGS shares in their latest 13F filing. A 13F shows quarter-end positions and arrives up to 45 days later.
| Fund | Of its portfolio | Value | Change | Quarter |
|---|---|---|---|---|
| Cathie WoodARK Investment Management | 0.72% | $111M | +21.6% | Q2 2026 |